Marker Therapeutics (MRKR) Amortization of Deferred Charges (2014 - 2023)

Marker Therapeutics (MRKR) has reported Amortization of Deferred Charges for 5 consecutive years, with $153518.0 the latest figure, recorded in Q1 2023.

• In Q1 2023, Amortization of Deferred Charges fell 40.47% year-over-year to $153518.0; the TTM figure through Mar 2023 stood at $786972.0 (down 22.84% YoY), while the FY2022 annual figure was $891343.0, down 12.07% from the prior year.
• Amortization of Deferred Charges grew to $153518.0 in Q1 2023 per MRKR's latest filing, from $151897.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $259170.0 in Q2 2022 and bottomed at $151897.0 in Q4 2022.
• Historically, Amortization of Deferred Charges has averaged $228724.0 across 3 years, with a median of $252606.0 in 2021.
• On a YoY basis, Amortization of Deferred Charges climbed as much as 2.6% in 2022 and fell as far as 40.59% in 2022.
• Marker Therapeutics' Amortization of Deferred Charges stood at $255697.0 in 2021, then slumped by 40.59% to $151897.0 in 2022, then increased by 1.07% to $153518.0 in 2023.
• Business Quant data shows MRKR's Amortization of Deferred Charges at $153518.0 in Q1 2023, $151897.0 in Q4 2022, and $222387.0 in Q3 2022.